ClinicalTrials.gg
CompletedNCT02114268Updated Nov 28, 2016Results posted

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

A Phase 1 interventional study of MEDI8897 Intravenous and Placebo in Respiratory Syncytial Virus Infections, sponsored by MedImmune LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.

Enrollment
5th of 12
342 · median 239
Started
2014
the only one that year
Phase 1
4 of 14
none open now
Registered
9th of 14
by date

Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2014, is one of 4 in phase 1, and was the 9th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca as a file.
02

Study summary

The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy adult participants.

Read the detailed description

This was a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of MEDI8897 compared to placebo when administered to healthy adult participants. There were 136 participants randomized to receive MEDI8897 or placebo at one site. Investigational product was delivered intravenously (IV) to 3 cohorts and intramuscularly (IM) to 2 cohorts. 4 different dose levels of investigational product were evaluated across the 5 cohorts. Participants were followed for approximately 1 year.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory Syncytial Virus, RSV
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Age 18 through 49 years and in good health by history, physical exam, and labs
  • Weight greater than or equal to (>=) 45 kilogram (kg) and less than or equal to (\<=) 110 kg at Screening
  • Written prior to performing any protocol related procedures, including Screening evaluations
  • Ability to complete the Follow-up period of 360 days

Key Exclusion Criteria:

  • Acute illness including fever >= 99.5 Fahrenheit (°F) on day of dosing
  • Any drug therapy within 7 days prior to Day 1 (except )
  • Receipt of any drug therapy within 120 days prior to investigational product dosing through 360 days after investigational product dosing
  • Previous receipt of a monoclonal antibody (mAb)
  • Pregnant or nursing mother
  • Concurrent enrollment in another interventional study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
342 participants (actual)

Study arms

  • Experimental
    MEDI8897 300 milligram (mg) Intravenous (IV)

    Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.

    Drug: MEDI8897 Intravenous

  • Experimental
    MEDI8897 1000 mg IV

    Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.

    Drug: MEDI8897 Intravenous

  • Experimental
    MEDI8897 3000 mg IV

    Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.

    Drug: MEDI8897 Intravenous

  • Experimental
    MEDI8897 100 mg Intramuscular (IM)

    Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.

    Drug: MEDI8897 Intramuscular

  • Experimental
    MEDI8897 300 mg IM

    Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.

    Drug: MEDI8897 Intramuscular

  • Placebo comparator
    Placebo

    Participants received placebo on Day 1.

    Drug: Placebo

Interventions

  • Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.

  • DrugPlacebo

    Participants received placebo on Day 1.

  • Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.

  • Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.

  • Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.

  • Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is defined as events present at baseline that worsened in intensity after administration of investigational products or events absent at baseline that emerged after administration of study drug, for the period extending to 391 (Day 361 ± 30 days) days after the last dose of study drug.

    Time frame: From start of study drug administration up to Day 391 (Day 361 +/- 30 days)

Secondary outcomes

  1. Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897

    The Tmax is defined as actual sampling time to reach maximum observed MEDI8897 concentration. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

    Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361

  2. Maximum Observed Serum Concentration (Cmax) for MEDI8897

    The Cmax is the maximum observed serum concentration of MEDI8897. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

    Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361

  3. Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) for MEDI8897

    The AUC (0-infinity) is the area under the serum concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the serum concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

    Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361

  4. Terminal Phase Elimination Half Life (t1/2) for MEDI8897

    The terminal elimination half-life (t1/2) is the time measured for the serum concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z). Here 'n' signifies participants evaluable for specified categories, for each arm, respectively. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

    Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361

  5. Systemic Clearance (CL) for MEDI8897

    Systemic Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after the dose was estimated by dividing the total administered dose by the Area Under the Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]). Apparent clearance (CL/F) for the IM dose groups. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

    Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361

  6. Volume of Distribution (Vz) for MEDI8897

    The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a study drug. Apparent volume of distribution (Vz/F) for the IM dose groups. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

    Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361

  7. Number of Participants With Positive Anti-Drug Antibody (ADA)

    Participants were tested for anti-drug antibody to MEDI8897 prior to enrollment, predose and postdose.

    Time frame: Predose and Day 15, 31, 91, 181, 271 and 361

07

Results

Posted Nov 28, 2016
Limitations and caveats
Physical examination parameters of participants were not evaluated.

Participant flow

Participant flow — Overall Study
MilestonePlaceboMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
Started34666678
Completed28556675
Not completed611003
Withdrew: Lost to follow-up411002
Withdrew: Withdrawal by subject100001
Withdrew: Withdrawn by site due to noncompliance100000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is defined as events present at baseline that worsened in intensity after administration of investigational products or events absent at baseline that emerged after administration of study drug, for the period extending to 391 (Day 361 ± 30 days) days after the last dose of study drug.

Time frame:
From start of study drug administration up to Day 391 (Day 361 +/- 30 days)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
participantsPlaceboMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
TEAEs21335448
TESAEs000002
SecondaryTime to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897

The Tmax is defined as actual sampling time to reach maximum observed MEDI8897 concentration. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

Time frame:
Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Reported as:
Mean · Day
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897
DayMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI88970.078 ± 1720.059 ± 00.209 ± 62.75.46 ± 71.49.42 ± 78.4
SecondaryMaximum Observed Serum Concentration (Cmax) for MEDI8897

The Cmax is the maximum observed serum concentration of MEDI8897. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

Time frame:
Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Reported as:
Mean · microgram per milliliter (mcg/ml)
Maximum Observed Serum Concentration (Cmax) for MEDI8897
microgram per milliliter (mcg/ml)MEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
Maximum Observed Serum Concentration (Cmax) for MEDI889796.98 ± 21.9333.80 ± 22.41163.32 ± 23.820.40 ± 29.447.48 ± 26.2
SecondaryArea Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) for MEDI8897

The AUC (0-infinity) is the area under the serum concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the serum concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

Time frame:
Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Reported as:
Mean · Day*microgram per milliliter
Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) for MEDI8897
Day*microgram per milliliterMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) for MEDI88976714.75 ± 21.725320.68 ± 1763580.33 ± 10.42249.11 ± 17.95193.73 ± 32.1
SecondaryTerminal Phase Elimination Half Life (t1/2) for MEDI8897

The terminal elimination half-life (t1/2) is the time measured for the serum concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z). Here 'n' signifies participants evaluable for specified categories, for each arm, respectively. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

Time frame:
Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Reported as:
Mean · Day
Terminal Phase Elimination Half Life (t1/2) for MEDI8897
DayMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
Terminal Phase Elimination Half Life (t1/2) for MEDI8897116.52 ± 19.692.0 ± 12.689.81 ± 18.2102.61 ± 11.385.29 ± 30.8
SecondarySystemic Clearance (CL) for MEDI8897

Systemic Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after the dose was estimated by dividing the total administered dose by the Area Under the Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]). Apparent clearance (CL/F) for the IM dose groups. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

Time frame:
Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Reported as:
Mean · ml per day
Systemic Clearance (CL) for MEDI8897
ml per dayMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
Systemic Clearance (CL) for MEDI889746.05 ± 17.340.33 ± 15.447.60 ± 10.645.46 ± 15.464.60 ± 37.7
SecondaryVolume of Distribution (Vz) for MEDI8897

The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a study drug. Apparent volume of distribution (Vz/F) for the IM dose groups. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).

Time frame:
Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Reported as:
Mean · milliliter (ml)
Volume of Distribution (Vz) for MEDI8897
milliliter (ml)MEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
Volume of Distribution (Vz) for MEDI88977694.15 ± 24.85426.89 ± 26.76137.69 ± 18.56808.78 ± 24.57455.90 ± 34.0
SecondaryNumber of Participants With Positive Anti-Drug Antibody (ADA)

Participants were tested for anti-drug antibody to MEDI8897 prior to enrollment, predose and postdose.

Time frame:
Predose and Day 15, 31, 91, 181, 271 and 361
Reported as:
Number · participants
Number of Participants With Positive Anti-Drug Antibody (ADA)
participantsPlaceboMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
Predose300005
At Any Time Postdose5010013

Adverse events

Collected over From Screening to Postdose Follow-up (up to 391 Days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/34 (0%)21/34 (61.8%)
MEDI8897 300 Milligram (mg) Intravenous (IV)—0/6 (0%)3/6 (50%)
MEDI8897 1000 Milligram (mg) Intravenous (IV)—0/6 (0%)3/6 (50%)
MEDI8897 3000 Milligram (mg) Intravenous (IV)—0/6 (0%)5/6 (83.3%)
MEDI8897 100 Milligram (mg) Intramuscular (IM)—0/6 (0%)4/6 (66.7%)
MEDI8897 300 Milligram (mg) Intramuscular (IM)—2/78 (2.6%)48/78 (61.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
AppendicitisInfections and infestations0/340/60/60/60/61/78
Gun shot woundInjury, poisoning and procedural complications0/340/60/60/60/61/78
Most frequent other events
Showing 10 of 89
Most frequent other events
EventPlaceboMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)
NauseaGastrointestinal disorders2/340/60/62/60/63/78
Urinary tract infectionInfections and infestations1/340/60/60/62/64/78
Upper respiratory tract infectionInfections and infestations3/341/61/60/61/616/78
HeadacheNervous system disorders6/340/61/61/60/67/78
Lacrimation increasedEye disorders1/340/61/60/60/60/78
ConstipationGastrointestinal disorders1/341/60/60/60/61/78
FlatulenceGastrointestinal disorders0/340/60/61/60/60/78
Food poisoningGastrointestinal disorders0/340/60/61/60/60/78
Injection site painGeneral disorders0/340/60/60/61/61/78
ConjunctivitisInfections and infestations0/340/60/61/60/61/78

Baseline characteristics

The As-treated Population included participants who receive any study investigational product.

Age, Continuous
Age, Continuous(Years)PlaceboMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)Total
Mean29.2 ± 8.634.5 ± 8.634.3 ± 5.633.5 ± 6.730.7 ± 7.830.3 ± 7.930.5 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI8897 300 Milligram (mg) Intravenous (IV)MEDI8897 1000 Milligram (mg) Intravenous (IV)MEDI8897 3000 Milligram (mg) Intravenous (IV)MEDI8897 100 Milligram (mg) Intramuscular (IM)MEDI8897 300 Milligram (mg) Intramuscular (IM)Total
Female1942363973
Male1524303963
08

Study locations

1 site
  • Research Site
    Overland Park, Kansas, United States
09

References and documents

Publications

  • Griffin MP, Khan AA, Esser MT, Jensen K, Takas T, Kankam MK, Villafana T, Dubovsky F. Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e01714-16. doi: 10.1128/AAC.01714-16. Print 2017 Mar. PubMed 27956428 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2014
First posted
Apr 15, 2014
Start
Apr 2014
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Nov 28, 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02114268
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Apr 15, 2014
Start date
Apr 2014
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Nov 28, 2016
Last update
Nov 28, 2016

Study contacts

M. Pamela Griffin, MD
study director · MedImmune LLC
Martin Kankam, MD, PhD, MPH
principal investigator · Study Site

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion